Kisplyx
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Lenvatinib
- Made by
- Eisai GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Eisai GmbH |
|---|---|
| Active substance | Lenvatinib |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01XE29 · Cancer treatments and immune-system medicines |
| Authorised on | 2016-08-25 |
| Last updated by the regulator | 2026-03-26 |
| EMA product number | EMEA/H/C/004224 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.